{"status": "Ok", "redirect_url": "https://www.businesswire.com/news/home/20260530259024/en/Incyte%E2%80%99s-Pivotal-frontMIND-Trial-Showed-Tafasitamab-Monjuvi%C2%AEMinjuvi%C2%AE-Combination-Significantly-Prolonged-Progression-free-Survival-Reducing-the-Risk-of-Disease-Progression-or-Death-by-25-in-Patients-with-Previously-Untreated-High-risk-DLBCL", "message": "News view counter 769102 successfully enlarged"}